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Abstract Benign breast disease (BBD) is diagnosed in
1–2 million women/year in the US, and while these
patients are known to be at substantially increased risk for
subsequent development of breast cancer, existing models
for risk assessment perform poorly at the individual level.
Here, we describe a DNA-microarray-based transcriptional
model for breast cancer risk prediction for patients with
sclerosing adenosis (SA), which represent  of all BBD
patients. A training set was developed from 86 patients
diagnosed with SA, of which 27 subsequently developed
cancer within 10 years (cases) and 59 remained cancer-free
at 10 years (controls). An diagonal linear discriminate
analysis-prediction model for prediction of cancer within
10 years (SA TTC10) was generated from transcriptional
profiles of FFPE biopsy-derived RNA. This model was
tested on a separate validation case–control set composed
of 65 SA patients. The SA TTC10 gene signature model,
composed of 35 gene features, achieved a clear and sig-
nificant separation between case and control with receiver
operating characteristic area under the curve of 0.913 in the
training set and 0.836 in the validation set. Our results
provide the first demonstration that benign breast tissue
contains transcriptional alterations that indicate risk of
breast cancer development, demonstrating that essential
precursor biomarkers of malignancy are present many
years prior to cancer development. Furthermore, the SA
TTC10 gene signature model, which can be assessed on
FFPE biopsies, constitutes a novel prognostic biomarker
for patients with SA.
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Introduction
Breast cancer (BC) is the most commonly diagnosed can-
cer in women in the US, with estimated incidence of more
than 230,000 new cases and 40,000 deaths expected in
2014 [1]. BC is most effectively treated when identified at
early stages of development; better identification of which
women are at increased risk for developing breast cancer
would have considerable benefit for optimal use of
surveillance resources. Currently, the most commonly used
method for assessment of breast cancer is the Breast
Cancer Risk Assessment Tool (BCRAT, also referred to as
the Gail model) [2], which works well to identify
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populations of women at increased BC risk, but which
performs less well when used to predict risk for individual
women [3, 4].
More than 1 million women per year in the US have
breast biopsies with benign findings; these women are
classified as having benign breast disease (BBD) and are
known to have significantly elevated risk for subsequent
development of breast cancer [5, 6]. BC risk for women
with BBD can be stratified by histological features present
in the benign biopsy, including type of lesion and degree of
lobular involution [5, 7–9]. An individualized risk assess-
ment model for women with BBD, designated the BBD-BC
model, was recently developed for women with BBD and
includes histologic features of the biopsy as well as other
demographic and clinical features [4]. The BBD-BC model
was found to provide improved performance for women
with BBD as compared to the BCRAT model; in a cohort
of women with BBD identified at the Mayo Clinic, the
BBD-BC had a Receiver Operating Characteristic area
under the curve (ROC AUC) of 0.665, while the BCRAT
had a ROC AUC of 0.567 [4]. The BBD-BC model thus
provided improved risk classification compared to the
BCRAT; however, the BBD-BC model was designed to
predict risk for all women with BBD. It is likely that better
discrimination of risk could be obtained by developing
models for specific subtypes of BBD.
Sclerosing adenosis (SA) is a common BBD lesion that
is characterized by epithelial proliferation, disordered aci-
nar architecture, and stromal fibrosis (Fig. 1) [5, 10, 11].
Investigation of the Mayo Clinic BBD cohort revealed that
SA was present in 28 % of the cohort and was associated
with an approximate doubling of risk of subsequent BC
[11]. This increased risk indicates that premalignant
changes are likely present in some patients with SA. We
obtained RNA from formalin-fixed, paraffin-embedded
SA-containing biopsies and sought transcriptional elements
that could predict subsequent cancer incidence. Our results
demonstrate the development and validation of the first
microarray-based gene signature to predict risk of later BC
from benign breast tissue and provide a template for a




This study sample comprises patients selected from the
Mayo BBD Cohort, which has been previously described
[5, 9]. The Mayo BBD Cohort includes 9854 women ages
18–85 who had excisional breast biopsy with benign
findings between 1967 and 1991 at Mayo Clinic (Roche-
ster, MN). Demographic descriptors and potential breast
cancer risk factors were identified via medical record
review and from self-response questionnaires [5, 9]. Over a
median of 18.9 years of follow-up, 924 of these women
have been diagnosed with BC. Informed consent was
obtained from each subject. All study procedures have been
approved by the Mayo Clinic Institutional Review Board.
Biopsy findings were classified into the following cate-
gories: non-proliferative fibrocystic changes (NP), prolif-
erative fibrocystic disease without atypia (PDWA), and
proliferative fibrocystic disease with atypia [i.e., atypical
hyperplasia (AH)] [12]. Sclerosing adenosis (SA) is a
proliferative lesion, without atypia, that consists of
enlarged and distorted lobules with prominent myoepithe-
lium and stromal fibrosis. Because of concerns with tissue
quality from the older biopsy specimens, eligibility for this
study was restricted to the 1486 women diagnosed with
PDWA and SA between the years of 1977 and 1991.
Two sets of breast cancer cases and controls from the
SA group were formed for study purposes: one for model
development (N = 86) and one for model validation
(N = 65). For each, an age-stratified random sample of
women with breast cancer at any time was selected, with
selection probabilities proportional to the size of the age
strata. Women from the last 10 years of the cohort
recruitment period (1982–1991) were preferentially sam-
pled, again under the assumption that tissue quality would
be higher for these women than for those from the earlier
years of the cohort. An equal number of controls were then
frequency matched to these cases based on 5-year age and
year of biopsy categories. The presence of SA lesions in the
case/control samples was confirmed and reviewed by a
second breast pathologist (AN). Study cohort demographic
and clinical characteristics are in Table 1.
▲
▲
Fig. 1 Histology of sclerosing adenosis (SA). H&E image of SA
(arrow) in field containing two normal lobules (arrowheads). Scale
bar 1 mm
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RNA extraction and gene expression profiling
RNA was extracted from FFPE samples using the High
Pure RNA Paraffin Kit (Roche Diagnostics, Mannheim,
Germany). The amount and quality of RNA were assessed
with ND-1000 Spectrophotometer (Nanodrop, Wilmington,
DE), and they were considered adequate for further anal-
ysis if the optical density 260/280 ratio was C1.8, and the
total RNA yield was C500 ng. Extracted RNA was labeled
and hybridized according to manufacturer’s instruction for
the Whole Genome DASL assay (Illumina, San Diego,
CA). All samples in the model development set had tech-
nical replicates. The first replicate was randomized to one
96-well plate for assay preparation, and the second repli-
cate for each sample had a different randomization to a
second 96-well plate. For the validation set, only 17 sam-
ples were profiled in replicate. Briefly, 200 ng of total
RNA was reverse transcribed with biotinylated oligo(dT)
and random nonamer primers. The resulting cDNA was
annealed to chimeric query oligonucleotides which contain
a gene-specific region and a universal primer sequence for
PCR amplification, and then bound to streptavidin-conju-
gated paramagnetic particles. The gene-specific oligonu-
cleotides were extended by second-strand cDNA synthesis
and then ligated. Subsequently, the products were seques-
tered by magnetic separation, washed to remove unbound
molecules, and then amplified by PCR with fluorophore-
labeled universal primers. The resulting PCR products
were purified, applied to Human HT-12 v.4 beadchips
(Illumina), and then hybridized for 16 h at 58 C. The
beadchips were washed and then scanned in a BeadArray
Reader using BeadScan v3 software (Illumina). Quality
control parameters were determined to be within normal
ranges before proceeding to the final data analysis. Sample
probe gene expression values for the 29,377 probes were
exported from Illumina Genomestudio and imported into
the software R [13] for normalization, additional quality
control, analysis, and prediction model development. The
agreement between technical replicates was analyzed for
correlation between model metrics in the first and second
Table 1 Characteristics of
study set and comparison to
overall SA patient cohort
Not selected (N = 1316) Study set (N = 170) p value
Age at BBD 0.3441
\45 301 (22.9 %) 40 (23.5 %)
45–55 447 (34.0 %) 66 (38.8 %)
55? 568 (43.2 %) 64 (37.6 %)
Year of benign biopsy 0.2938
1977–1981 241 (18.3 %) 37 (21.8 %)
1982–1986 501 (38.1 %) 55 (32.4 %)
1987–1991 574 (43.6 %) 78 (45.9 %)
Breast cancer status \0.0001
Unaffected 1202 (91.3 %) 90 (52.9 %)
Breast cancer 114 (8.7 %) 80 (47.1 %)
Overall impression 0.0815
PROL. DIS W/O ATYPIA 1187 (90.2 %) 146 (85.9 %)
PROL. DIS W/ATYPIA 129 (9.8 %) 24 (14.1 %)
Atrophy 0.0036
Missing 46 7
NO 148 (11.7 %) 31 (19.0 %)
1–74 % TDLU 996 (78.4 %) 125 (76.7 %)
[75 % TDLU 126 (9.9 %) 7 (4.3 %)
Columnar alteration 0.0730
Missing 1 0
NO 614 (46.7 %) 67 (39.4 %)
Marked 701 (53.3 %) 103 (60.6 %)
Family history of breast cancer 0.0249
Missing 3 0
None 814 (62.0 %) 87 (51.2 %)
Weak 337 (25.7 %) 56 (32.9 %)
Strong 162 (12.3 %) 27 (15.9 %)
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replicates for the model development set and between the
first and second replicates for the validation set respec-
tively (Supplementary Fig. 1).
Gene expression intensities from only the model
development set were quantile-normalized in an iterative
fashion using the normalization stress metric as described
by Mahoney et al. to exclude failed samples [14]. Samples
and their respective replicates were kept for further anal-
ysis if the normalization stress metric was less than
0.585 = log2(1.5). The model validation set was quantile-
normalized separately to the final normalized distribution
from the model development set. Normalized gene
expression values were transformed to the log2 scale for
analysis.
The complete description of the methods involved in SA
TTC10 (cancer within 10 years) model development and
analysis, including extensive internal model validation, is
provided in Supplemental Methods.
Results
We used the development of BC at 10 years as the primary
end point for model development. The 86 patients in the
model development set included 27 TTC10-cases and 59
TTC10-controls, and the 65 patients in the validation set
included 10 TTC10-cases and 55 TTC10-controls, with 3
and 12 replicates, respectively. The optimum-filtering
strategy of 45 % detected-p value\0.01 and 35 probes was
chosen based on the local minimum (to prevent over-fit-
ting) of the average prediction error from the 100 Monte
Carlo cross-validation test sets (Fig. 2a), which filtered out
8873 probes from further analysis (Fig. 2b). The 35 probes
selected as final-model features are shown in Supplemen-
tary Table 1.
Prediction performance for the model development set
was ROC AUC = 0.91 (95 % CI, 0.87, 0.95) with a pre-
diction accuracy of 80 % (95 % CI 70, 88 %; Fig. 2c). The
independent validation set had an ROC AUC = 0.84
(95 % CI 0.75, 0.92) with a prediction accuracy of 58 %
(95 % CI 46, 71 %; Fig. 2d). Actual TTC10 case/control
status and the continuous version of the DLDA prediction
model metric for both the model development and vali-
dation sets are displayed (Fig. 2e). Full prediction perfor-
mance and accuracy metrics are shown in Table 2. Actual
time-to-cancer based on the predicted group for each
sample is displayed in Kaplan–Meier plots (Fig. 3).
Combined BCRAT ? TTC10 and BBD-BC ? TTC10
models were built for the samples where both the BCRAT
and BBD-BC model metrics were available (Fig. 4). All
the patient samples in the model development set could be
used, and 10 TTC10 cases and 41 TTC10 controls were
available from the validation set. For the training set, the
TTC10 model improved discrimination of the BCRAT
model, with AUC = 0.64 (95 % CI 0.57–0.71) for BCRAT
alone, 0.91 (95 % CI 0.87–0.95) for BCRAT combined
with TTC10, and 0.91 (95 % CI 0.87–0.95) for TTC10
alone (Fig. 4a). The TTC10 model also improved dis-
crimination of the BBD-BC model, with AUC of 0.63
(95 % CI 0.56–0.70) for BBD-BC alone, 0.93 (95 % CI
0.89–0.97) for BBD-BC combined with TTC10, and 0.91
(95 % CI 0.87–0.95) for TTC10 alone (Fig. 4b). Similarly,
Fig. 2 Development and validation of SA TTC10 model. a Mean
area above the receiver operating characteristic (ROC) curve plotted
against the number of top genes included in the classifiers. b Plot of
average gene expression values indicating probes which were used for
the model building ([45 % positive expression, p\ 0.1 for differ-
ence between cases and controls) and locations of which probes were
included in the model. Probes passing the filtering threshold are
shown in red, those filtered out are shown in blue, and those probes
selected as final-model features are shown as large black dots. c,
d ROC for SA TTC10 model applied to training set (c; N = 86) and
validation set (d; N = 65). e SA TTC10 predictions for training and
validation dataset cases and controls. The vertical dashed line
separates the samples into those predicted to be a TTC10-control
(prediction metric B0) or TTC10-case (prediction metric[0)
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for the validation set, the TTC10 model also improved
discrimination: AUC = 0.55 for BCRAT alone, 0.79
(95 % CI 0.70–0.87) for BCRAT combined with TTC10,
and 0.80 (95 % CI 0.71–0.89) when TTC10 is used alone
(Fig. 4c). Improvements of TTC10 with the BBD-BC
model are as follows: AUC = 0.75 (95 % CI 0.65–0.85)
for BBD-BC alone, 0.82 (95 % CI 0.73–0.91) for BBD-BC
combined with TTC10, and 0.80 (95 % CI 0.71–0.89) for
Pred: no BC within 10 years
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Fig. 3 Time-to-Cancer Distributions within SA TTC10 prediction
groups. a, b Kaplan–Meier plots visualizing the distribution of actual
time-to-cancer within predicted case/control groups in training
(a) and validation (b) cohorts
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TTC10SA: 0.91 ± 0.04
BCRAT: 0.64 ± 0.07
BCRAT+TTC10SA: 0.91 ± 0.04
TTC10SA: 0.91 ± 0.04
BBD-BC: 0.63 ± 0.07
BBD-BC+TTC10SA: 0.93 ± 0.04
TTC10SA: 0.80 ± 0.09
BCRAT: 0.55 ± 0.10
BCRAT+TTC10SA: 0.79 ± 0.09
TTC10SA: 0.80 ± 0.09
BBD-BC: 0.75 ± 0.10
BBD-BC+TTC10SA: 0.82 ± 0.09
Fig. 4 Combination of SA TTC10 model with BCRAT or BBD-BC
models improves performance of each. a, b ROC for BCRAT (a) and
BBD-BC (b) models with SA training set. c, d ROC for SA TTC10
combined with BCRAT (c) and BBD-BC (d) models for SA
validation set
Table 2 Model metrics for the TTC10 model, unless otherwise specified
Cases/controls TTC10
Model development Validation set
27/59 10/55
Number of final-model features 35 35
TTC10 AUC: only samples with BCRAT and BBD-BC risk scores 0.91 (0.87, 0.95) 0.80 (0.71, 0.89)
AUC: BCRAT alone 0.64 (0.58, 0.71) 0.56 (0.45, 0.66)
AUC: BCRAT ? TTC10 0.91 (0.87, 0.95) 0.79 (0.70, 0.88)
AUC: BBD-BC alone 0.63 (0.56, 0.70) 0.75 (0.66, 0.84)
AUC: BBD-BC ? TTC10 0.93 (0.89, 0.96) 0.82 (0.73, 0.91)
True positives 26 9
True negatives 43 29
False positives 16 26
False negatives 1 1
Accuracy 0.80 (0.70, 0.88) 0.58 (0.46, 0.71)
Sensitivity 0.96 (0.81, 1.0) 0.90 (0.56, 1.0)
Specificity 0.73 (0.60, 0.84) 0.53 (0.39, 0.66)
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TTC10 alone (Fig. 4d). Thus, in women with SA, the SA
TTC10 model provides improved and independent risk
assessment compared to those of the BCRAT and the
BBD-BC models.
Discussion
We have developed a microarray-based gene signature in
benign breast tissue that accurately discriminates between
patients that will and will not develop breast cancer within
10 years. Specifically, the signature pertains to women
with sclerosing adenosis, a common proliferative finding
present in about 25 % of all benign biopsies. The signature
also performed well in an independent validation set of
women with sclerosing adenosis. This molecular-based
model, based in a specific subtype of BBD, performs
substantially better than traditional models containing
clinical and histologic features only; in the validation set,
the TTC10 signature provided an improvement in AUC of
0.07 above the BBD-BC model alone and 0.23 above
BCRAT alone.
There are multiple advantages to a microarray-based
signature based on FFPE tissue. The risk signature is not
dependent on pathology interpretation and provides risk
information that is independent of risk stratification
resulting from standard clinical models. Furthermore, the
use of FFPE biopsy tissue ensures widespread applicability
of this model, as FFPE is the most common method for
tissue preservation and is the standard for tissue archiving.
Compared to assays requiring fresh/frozen tissue, an FFPE-
based assay will facilitate clinical implementation since no
changes in sample collection and processing are needed.
Analysis of the 35 individual probes that compose the
TTC10 model revealed a number of genes that have been
previously implicated in breast cancer progression.
NDRG3, encoding the N-Myc Downstream-Regulated
Gene 3 Protein, had a negative coefficient, indicating that
increased relative expression was associated with reduced
BC risk; NDRG3 has been identified as activated by the
estrogen receptor-b (ERb) and as a component of an
antiproliferative response induced by ERb in the T47D
breast cancer cell line [15, 16]. Other probes with a neg-
ative coefficient include NPNT1, encoding the protein
nephronectin, which has been found to be downregulated in
breast cancer cells that acquire the ability to metastasize to
the liver [17], and PSMB1, encoding the proteasome
macropain subunit-b1, has been identified as a component
of a protein interaction network prognostic for BC outcome
[18]. GEMIN2, encoding gem (nuclear organelle) associ-
ated protein 2, also designated as SIP1, has a positive
coefficient and thus increased expression of this gene was
associated with increased BC risk; GEMIN2/SIP1 has been
extensively studied as a mediator of the epithelial-mes-
enchymal transition and as a suppressor of the differenti-
ated epithelial phenotype [19–21]. Other probes with a
positive coefficient include MTHFD2, encoding
methylenetetrahydrofolate dehydrogenase-2, a metabolic
regulator associated with poor prognosis for BC patients
and as an inducer of BC cell invasion and metastasis [22–
25], and UFL1, encoding UFM1-specific ligase 1, recently
identified as a component of a protein complex critical for
ERa transactivation and breast cancer development [26].
Strengths of our study include our focus on a common
proliferative lesion, use of a large cohort as a sampling
frame for cases and controls, use of FFPE tissues which
should translate well to current clinical practice, and vali-
dation in an independent dataset. The threshold used to
determine case status from the predicted score can be
optimized in future studies to minimize false positives and
false negatives while balancing the consequences of each.
We chose to use whole tissue sections rather than laser-
microdissected lesions, since SA reflects perturbations in
both the epithelial and stromal compartments, and thus, a
model incorporating both contains information about how
elements of the tumor microenvironment contribute to
cancer development. As a weakness, our focus on SA
limits the application of our signature to this particular
patient group, but we estimate that about 250,000 women
per year receive a diagnosis of SA on their benign breast
biopsies; molecular predictive models for patients with
BBDs containing other common proliferative lesions can
also be studied.
Furthermore, our sample selection procedure included
over-sampling cases in order to improve power to dis-
criminate between patients that would go on to develop
breast cancer from those that would not. As a result, the
prevalence of breast cancer events within the development
and validation samples do not reflect the population
prevalence of breast cancer, and therefore, this gene sig-
nature cannot be directly used to obtain individualized risk
predictions, which will be the subject of future studies.
However, this study importantly provides a proof of prin-
ciple, where we have now identified genes that discriminate
with a high level of accuracy, which will form the basis of
a future risk prediction model combined with clinical
information, as in (Ref [4]). Additionally, the use of the
endpoint of time-to-cancer within 10 years provided
improved discriminative ability relative to previously
developed models. Unsurprisingly, this suggests that a
molecular signature derived from a benign biopsy will be a
better predictor of earlier cancer occurrences.
In conclusion, this is the first predictive transcriptional
model derived from benign breast tissue that can distin-
guish between patients that developed BC within 10 years
from those who did not. We show that this molecular-based
692 Breast Cancer Res Treat (2015) 152:687–694
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profile, focused on patients with SA, provides improvement
over previous models that do not include molecular data.
We now plan to conduct studies designed to accurately
estimate risk with this model and to develop additional
signature models for other categories of BBD. By identi-
fying higher risk women among those with SA, this model
can help to stratify women into groups who would benefit
from more intensive surveillance strategies. Additionally,
as our results demonstrate that transcriptional features
associated with BC are present in SA-containing biopsies
more than a decade before cancer development, our study
provides insight into novel potential targets for chemo-
prevention specific for patients with SA.
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